- Inhibitors of c-Jun N-terminal kinases
-
The present invention relates to compounds that are inhibitors of c-jun N-terminal kinase 1, 2, or 3 (JNK1, JNK2, or JNK3), compositions containing the compounds and the use of the compounds in the prevention or treatment of disorders regulated by the activation of JNK1, JNK2 and JNK3.
- -
-
Page/Page column 61
(2008/06/13)
-
- Discovery of potent, highly selective, and orally bioavailable pyridine carboxamide c-Jun NH2-terminal kinase inhibitors
-
C-Jun NH2 terminal kinases (JNKs) are important cell signaling enzymes. JNK1 plays a central role in linking obesity and insulin resistance. JNK2 and JNK3 may be involved in inflammatory and neurological disorders, respectively. Small-molecule JNK inhibitors could be valuable tools to study the therapeutic benefits of inhibiting these enzymes and as leads for potential drugs targeting JNKs. In this report, we disclose a series of potent and highly selective JNK inhibitors with good pharmacokinetic profiles.
- Zhao, Hongyu,Serby, Michael D.,Xin, Zhili,Szczepankiewicz, Bruce G.,Liu, Mei,Kosogof, Christi,Liu, Bo,Nelson, Lissa T. J.,Johnson, Eric F.,Wang, Sanyi,Pederson, Terry,Gum, Rebecca J.,Clampit, Jill E.,Haasch, Deanna L.,Abad-Zapatero, Cele,Fry, Elizabeth H.,Rondinone, Cristina,Trevillyan, James M.,Sham, Hing L.,Liu, Gang
-
p. 4455 - 4458
(2007/10/03)
-